Immunotherapy in glioblastoma: emerging options in precision medicine

Tiffany R. Hodges; Sherise D. Ferguson; Amy B. Heimberger

doi:10.2217/cns-2016-0009

Immunotherapy in glioblastoma: emerging options in precision medicine

Tiffany R. Hodges, Sherise D. Ferguson, Amy B. Heimberger

Research output: Contribution to journal › Review article › peer-review

9 Scopus citations

Abstract

Immunotherapy for glioblastoma (GBM) provides a unique opportunity for targeted therapies for each patient, addressing individual variability in genes, tumor biomarkers and clinical profile. As immunotherapy has the potential to specifically target tumor cells with minimal risk to normal tissue, several immunotherapeutic strategies are currently being evaluated in clinical trials in GBM. With the Precision Medicine Initiative being announced in the President's State of the Union Address in 2016, GBM immunotherapy provides a useful platform for changing the landscape in treating patients with difficult disease.

Original language	English (US)
Pages (from-to)	175-186
Number of pages	12
Journal	CNS oncology
Volume	5
Issue number	3
DOIs	https://doi.org/10.2217/cns-2016-0009
State	Published - Jul 1 2016

Keywords

glioblastoma
immunotherapy
precision medicine

ASJC Scopus subject areas

General Medicine

Access to Document

10.2217/cns-2016-0009

Cite this

@article{e7280bcf14b846798c2ccc018ec0a7ee,

title = "Immunotherapy in glioblastoma: emerging options in precision medicine",

abstract = "Immunotherapy for glioblastoma (GBM) provides a unique opportunity for targeted therapies for each patient, addressing individual variability in genes, tumor biomarkers and clinical profile. As immunotherapy has the potential to specifically target tumor cells with minimal risk to normal tissue, several immunotherapeutic strategies are currently being evaluated in clinical trials in GBM. With the Precision Medicine Initiative being announced in the President's State of the Union Address in 2016, GBM immunotherapy provides a useful platform for changing the landscape in treating patients with difficult disease.",

keywords = "glioblastoma, immunotherapy, precision medicine",

author = "Hodges, {Tiffany R.} and Ferguson, {Sherise D.} and Heimberger, {Amy B.}",

year = "2016",

month = jul,

day = "1",

doi = "10.2217/cns-2016-0009",

language = "English (US)",

volume = "5",

pages = "175--186",

journal = "CNS oncology",

issn = "2045-0915",

publisher = "Future Medicine Ltd.",

number = "3",

}

TY - JOUR

T1 - Immunotherapy in glioblastoma

T2 - emerging options in precision medicine

AU - Hodges, Tiffany R.

AU - Ferguson, Sherise D.

AU - Heimberger, Amy B.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Immunotherapy for glioblastoma (GBM) provides a unique opportunity for targeted therapies for each patient, addressing individual variability in genes, tumor biomarkers and clinical profile. As immunotherapy has the potential to specifically target tumor cells with minimal risk to normal tissue, several immunotherapeutic strategies are currently being evaluated in clinical trials in GBM. With the Precision Medicine Initiative being announced in the President's State of the Union Address in 2016, GBM immunotherapy provides a useful platform for changing the landscape in treating patients with difficult disease.

AB - Immunotherapy for glioblastoma (GBM) provides a unique opportunity for targeted therapies for each patient, addressing individual variability in genes, tumor biomarkers and clinical profile. As immunotherapy has the potential to specifically target tumor cells with minimal risk to normal tissue, several immunotherapeutic strategies are currently being evaluated in clinical trials in GBM. With the Precision Medicine Initiative being announced in the President's State of the Union Address in 2016, GBM immunotherapy provides a useful platform for changing the landscape in treating patients with difficult disease.

KW - glioblastoma

KW - immunotherapy

KW - precision medicine

UR - http://www.scopus.com/inward/record.url?scp=85017516210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017516210&partnerID=8YFLogxK

U2 - 10.2217/cns-2016-0009

DO - 10.2217/cns-2016-0009

M3 - Review article

C2 - 27225028

SN - 2045-0915

VL - 5

SP - 175

EP - 186

JO - CNS oncology

JF - CNS oncology

IS - 3

ER -

Immunotherapy in glioblastoma: emerging options in precision medicine

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this